Validated UV-VIS Spectrophotometric Method and Stability Assessment of Extemporaneously Prepared Ceftazidime Ophthalmic Solution for Hospital Use

Abstract:

A simple, rapid and cost effective UV-VIS spectrophotometric method was validated and applied for stability assessment of 5% ceftazidime in extemporaneous ophthalmic solution in various conditions. Ceftazidime dissolving in sterile water showed the maximum absorbance (λ_max) at 256 nm and no interference was observed. The method validation was determined in term of linearity, intra-day and inter-day precision, accuracy, limit of detection (LOD) and limit of quantitation (LOQ) according to ICH guideline. Spectrophotometric response was linear with r² = 0.9998 in the range of 5-25 μg/mL. The mean recovery was 99.38% with percent relative standard deviations (%RSDs) of 0.83. Intra-day and inter-day precision showed %RSDs of < 1.00%. LOD and LOQ were 2.60 and 7.88 μg/mL, respectively. The method was reliable for stability study of extemporaneous ceftazidime ophthalmic solution. Results showed that the amount of ceftazidime in extemporaneous formulation stored in both ambient and accelerated conditions dramatically decreased within 1 day. However, the preparation was stable at 2-8 °C for 7 days. In conclusion, the storage temperature had greatly impact on ceftazidime ophthalmic solution therefore it should be kept in the refrigerator for a week and its stability could be monitored using the simple spectrophotometric method.

• Periodical: Advanced Materials Research (Volume 1060)
• Pages: 235-239
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.1060.235
• Online since: December 2014
• Authors: Danuch Panchapornpon*, Noppadol Chongcherdsak, Nantana Nuchtavorn, Chamaiporn Burimart, Naphaparin Simmasut, Suchanya Karnlaong
• Keywords: Ceftazidime, Ophthalmic Solution, Stability, UV-Vis Spectrophotometric

References

[1] M. Boarder, D. Newby and P. Navti: Pharmacology for pharmacist and the health sciences (Oxford University Press, USA 2010).

[2] J. D. Bartlett and S.D. Jaanus: Clinical Ocular Pharmacology (Elsevier Health Sciences, USA 2008).

[3] A. Kodym, A. Wis¢niewski, D. Kniola and M. Olejniczak: Acta Polan. Pharm. Vol. 68 (2011), pp.555-564.

[4] M. Zajac, J. Siwek and I. Muszalska: Acta Polan. Pharm. Vol. 55 (1998), pp.275-278.

[5] P. Favetta, C. Allombert, C. Breysse, C. Dufresne, J. Guitton and J. Bureau: J. Pharm. Biomed. Anal. Vol. 27 (2002), pp.873-879.

DOI: 10.1016/s0731-7085(01)00588-x

[6] A.H. Moreno and H.R.N. Salgado: J. Phys. Chem. Vol. 2 (2012), pp.6-11.

[7] A. Farina, R. Porra, V. Cotichini and A. Doldo: J. Pharm. Biomed. Anal. Vol. 20 (1990), pp.521-530.

[8] A.R. Barnest and S. Nasht: J. Clin. Pharm. Ther. Vol. 24 (1999), pp.299-302.

[9] A. Kodym, D. Hapka-Zmich, M. Golab and M. Gwizdala: Acta Pol. Pharm. Vol. 68 (2011), pp.99-107.

[10] ICH expert working group: ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1) (2005c).

DOI: 10.1002/9781118971147.ch5

[11] H. Servais and P.M. Tulkens: Antimicrob. Agents Chemother. Vol. 45 (2001), pp.2643-2647.